TLDR Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
The document from 2006 discusses the emergence of novel targeted therapies for cancer and the associated non-rash skin toxicities that often lead to treatment delays or discontinuation. These toxicities include skin hyperpigmentation, xerosis (dry skin), pruritus (itching), changes in hair growth and color, alterations in nails and the area around them, and hand-foot skin reactions. The review emphasizes the importance of early recognition and diagnosis of these side effects to allow for prompt treatment or adjustment of the therapy dosage. It provides an overview of the dermatologic toxicities seen with these agents and offers guidelines for their management.
90 citations,
August 2006 in “British Journal of Dermatology” PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.
78 citations,
June 2005 in “Annals of oncology” Cetuximab can cause excessive eyelash growth.
65 citations,
November 2004 in “Journal of the American Academy of Dermatology” Bimatoprost can cause excessive eyelash growth.
234 citations,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
73 citations,
September 2003 in “Journal of Pharmacology and Experimental Therapeutics” Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.
38 citations,
July 1998 in “Journal of surgical oncology” A woman with breast cancer developed a rare condition causing excessive fine hair growth on her face and body.
107 citations,
June 1997 in “PubMed” EGFR is essential for normal hair development and follicle differentiation.
15 citations,
February 2017 in “Nursing Clinics of North America” Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.
29 citations,
September 2017 in “Oncology and therapy” The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
18 citations,
January 2017 in “Postępy Dermatologii i Alergologii” EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
2 citations,
October 2018 in “Springer eBooks” Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
January 2016 in “Kafkas Journal of Medical Sciences” Turkish pregnant women commonly experienced skin issues like itching and acne, and doctors mainly used topical treatments due to safety concerns during pregnancy.
